Log In
BCIQ
Print this Print this
 

Imdur

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionOral extended-release formulation of isosorbide mononitrate (ISMN)
Molecular Target
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationAngina
Indication DetailsPrevent angina pectoris due to coronary heart disease
Regulatory Designation
PartnerChina Medical System Holdings Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$190.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/29/2016

$190.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today